Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
antiviral drug
|
| gptkbp:approvedBy |
2005
|
| gptkbp:ATCCode |
gptkb:J05AF10
|
| gptkbp:bioavailability |
~100%
|
| gptkbp:brand |
gptkb:Baraclude
|
| gptkbp:CASNumber |
gptkb:142217-69-4
|
| gptkbp:contraindication |
HIV infection without HAART
|
| gptkbp:developedBy |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:drugClass |
antiviral drug
|
| gptkbp:eliminationHalfLife |
128–149 hours (intracellular)
|
| gptkbp:excretion |
renal
|
| gptkbp:hasMolecularFormula |
C12H15N5O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
Entecavir
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits HBV DNA polymerase
|
| gptkbp:metabolism |
minimal
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:proteinBinding |
13%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
dizziness fatigue headache lactic acidosis |
| gptkbp:synonym |
gptkb:ETV
BMS-200475 |
| gptkbp:usedFor |
hepatitis B virus infection
|
| gptkbp:bfsParent |
gptkb:J05AE03
|
| gptkbp:bfsLayer |
7
|